← All trials
NCT02072070
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Aug 1, 2015
- Completion date
- Aug 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 163
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- TissueGene, Inc.Lead sponsor
- Inha UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Seoul National UniversityStudy chair
- University of UlsanOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Ewha Womans UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.